HSV-2 dose | FSL-1 2 μg 24 h priora | FSL-1 2 μg 6 h prior | DPBS vehicle control |
---|
(pfu) | %Infectedb | %Survivalc | %Infected | %Survival | %Infected | %Survival |
---|
1 × 101 | NDd | ND | ND | ND | 30 | 70 |
1 × 102 | 30 | 70 | 10e | 90 | 70 | 50 |
1 × 103 | 50e | 50e | 100 | 40 | 100 | 0 |
1 × 104 | 90 | 10 | 100 | 0 | ND | ND |
ID
50
f
| 760 (80-7000) | 260 (10-6000) | 31 (10-80) |
LD
50
g
| 760 (80-7000) | 660 (300-1000) | 68 (7-700) |
- a Intravaginal application of FSL-1 or DPBS vehicle control at indicated times prior to vaginal HSV-2 inoculation (n = 10 mice/treatment at each HSV-2 dose).
- b Percentage of mice with infectious virus in d2 vaginal swabs.
- c Percentage of mice that survived HSV-2 vaginal challenge up to d14 PI.
- d ND, not determined.
- e p < 0.05 compared to vehicle control (Fisher's exact test).
- f Dose of the virus required to infect 50% of the mice based on %Infected data; ID50 (95% confidence interval).
- g Dose of the virus required to cause lethal outcomes in 50% of the mice based on % survival data; LD50 (95% confidence interval).